Bioptik TechnologyROCO:4161 68 OCF Yield % is 4.36 as of Jul. 12, 2026, which is 140% above its 10-year median of 1.82. GuruFocus rates ROCO:4161 with a GF Score™ of 68/100 and a GF Value™ of NT$27.79 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Bioptik Technology ranks better than 62.44% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Bioptik Technology's OCF Yield % or its related term are showing as below:
ROCO:4161'
s OCF Yield % Range Over the Past 10 Years
Min: -6.88 Med: 1.82 Max: 13.18
Current: 4.36
During the past 13 years, the highest OCF Yield % of Bioptik Technology was 13.18%. The lowest was -6.88%. And the median was 1.82%.
ROCO:4161's OCF Yield % is ranked better than 62.44% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 1.7
vs ROCO:4161: 4.36
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Bioptik Technology OCF Yield % Related Terms
Bioptik Technology OCF Yield % Historical Data
* Premium members only.
The historical data trend for Bioptik Technology's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4161 vs ABT, SYK, MDT: OCF Yield % Comparison
For the Medical Devices subindustry, Bioptik Technology's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioptik Technology OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioptik Technology's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Bioptik Technology's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioptik Technology (ROCO:4161) has a OCF Yield % of 4.36 as of Jul. 12, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Bioptik Technology and its competitors. This is 140% above median its historical median of 1.82. According to the industry distribution chart, Bioptik Technology ranks #320 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 37.6%.
Is Bioptik Technology's OCF Yield % too high?
Bioptik Technology's current OCF Yield % of 4.36 is 140% above median its 10-year median of 1.82. The Medical Devices & Instruments industry median OCF Yield % is 1.70. Bioptik Technology's value of 4.36 is 156.5% above this industry median. Based on the distribution chart, Bioptik Technology ranks #320 out of 852 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bioptik Technology has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioptik Technology's OCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bioptik Technology ranks #320 out of 852 companies for OCF Yield %. This puts Bioptik Technology in the upper half of its industry. The industry median OCF Yield % is 1.70. Bioptik Technology's value of 4.36 is 156.5% above this benchmark. While the company's 10-year median is 1.82 vs. the industry median of 1.70, Bioptik Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.70, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioptik Technology's current OCF Yield % of 4.36 is 156.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Bioptik Technology and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioptik Technology's current OCF Yield % is 4.36, which is 140% above median its own 10-year median of 1.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioptik Technology stock overvalued right now?
Based on GuruFocus' analysis, Bioptik Technology (ROCO:4161) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.79, compared to a current price of NT$23.00 — trading 17.2% below its estimated fair value. The current OCF Yield % is 4.36, which is 140% above median its 10-year median of 1.82 and 156.5% above the Medical Devices & Instruments industry median of 1.70. Bioptik Technology's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Bioptik Technology (ROCO:4161), the current OCF Yield % is 4.36 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioptik Technology (ROCO:4161) Overvalued in 2026?
Based on GuruFocus' analysis, Bioptik Technology stock appears to be undervalued.
The current stock price of NT$23.00 is trading 17.2% below its estimated GF Value™ of NT$27.79.
GuruFocus considers Bioptik Technology to be Modestly Undervalued.
Key valuation signals for ROCO:4161:
OCF Yield %: 4.36 (140% above median its 10-year median of 1.82)
GF Value™: NT$27.79 vs. price of NT$23.00 (17.2% below fair value)
Industry Position: 156.5% above the Medical Devices & Instruments median (#320 of 852)
No single metric tells the full story. See the ROCO:4161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioptik Technology Inc is a Taiwan-based company engaged in the research, development, production, and sale of medical devices and reagents. The company is also focused on developing skin care products and aims to engage in developing bioenergy, Astaxanthin, and Cellulose Bioethanol. It is involved in the business areas of Home care medical devices, Skincare- Its own brand, Dietary supplement OEM and ODM, Skincare- OEM and ODM, and Biodiesel. In the Home care business area, the company provides Easy Touch blood glucose monitoring, and blood cholesterol and uric acid monitoring systems, as well as its strips.
68GF Score
Get the complete analysis for ROCO:4161
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4161 has been successfully added to your 
